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Background: Many patients on hemodialysis do not have adequate anatomy for native arteriovenous fistulas. In these
patients, synthetic conduits remain an alternative option for permanent hemodialysis access. We sought to compare the
standard cuffed expanded polytetrafluoroethylene (ePTFE) graft with the bovine carotid artery (BCA) graft.
Methods: This was a prospective, randomized controlled trial that was set in an academic medical center. We enrolled 26
patients in the BCA group and 27 patients in the ePTFE group. Primary, assisted primary, and secondary patency were
calculated using the Kaplan-Meier method. Complications were monitored and are reported.
Results: Although there was no significant difference in secondary patency rates, primary and assisted primary patency
rates were significantly higher in BCA than in the ePTFE grafts (60.5% vs 10.1% and 60.5% vs 20.8% at 1 year,
respectively). The BCA graft survival advantage was most profound in the upper arm grafts with significantly higher
primary and assisted patency rates (P < .0001 and .0005, respectively). The total number of interventions (upper arm
grafts) and total number of angioplasties (overall and upper arm) required to maintain patency were significantly fewer
in the BCA group. The most common complication was graft thrombosis which occurred 0.34  0.09 times per patient
year in the BCA group compared to 0.77  0.16 times per patient year in the ePTFE group, P  .01.
Conclusion:The BCA graft is an excellent option for patients on hemodialysis that are not suitable for native arteriovenous
fistulas, as these grafts required fewer interventions than the ePTFE grafts to maintain patency. (J Vasc Surg 2011;53:
1640-8.)
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tThe Kidney Disease Outcomes Quality Initiative
(KDOQI) guidelines urge providers to consider all patients
for an autologous arteriovenous fistula (AVF) as the first
line for permanent hemodialysis access.1 Unfortunately,
there are many patients that are not surgical candidates for
native fistulas because of inadequate arterial or venous
anatomy and thus require grafts for permanent vascular
access. Currently, grafts constructed with expanded poly-
tetrafluoroethylene (ePTFE) remain the most commonly
used conduits for nonautologous arteriovenous (AV) ac-
cess. However, these grafts are inferior to native AVF in
terms of longevity and infectious complications.2-4 As a
result, there remains considerable interest in the develop-
ment of bioprosthetic conduits that would mimic the com-
pliance of native tissue and be more resistant to intimal
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1640yperplasia and wall degeneration seen with synthetic
rafts.5
The use of bovine carotid artery (BCA) heterograft for
emodialysis access was first reported by Chinitz et al6 and
as used extensively by many centers in the 1970s.7-16
owever, with the advent of ePTFE grafts later that de-
ade, BCA grafts fell out of favor despite the lack of data to
ccount for the change in paradigm.16
With the efficient and effective endovascular techniques
ow available to manage complications along with im-
rovements to BCAmanufacturing, we felt revisiting BCAs
s AV conduits for hemodialysis would be worthwhile.
Here we report our results of a prospective, random-
zed trial comparing cuffed ePTFE grafts with the Artegraft
CA (Artegraft, North Brunswick, NJ) as conduits for
ermanent hemodialysis access. We reviewed the location
f graft placement, primary, assisted primary and secondary
atency, and overall complications.
ETHODS
Study group. Between April 4, 2006 and February 2,
009, a total of 220 arteriovenous graft (AVG)-related
urgeries (placement, revision, and thrombectomy) were
erformed at the Massachusetts General Hospital (MGH).
nrollment in this study was open to all 110 patients with
VG placement that were not candidates for a native AVF
s permanent AV access. Of these patients, 57 who gave
heir consent to enroll into the study were prospectively
andomized to receive either the Artegraft BVA (Artegraft)
patient randomization and exclusion.
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Volume 53, Number 6 Kennealey et al 1641or cuffed ePTFE graft. In this study, we exclusively used
cuffed ePTFE grafts (Venaflo, Bard Peripheral Vascular,
Tempe, Ariz) in all control cases, because better patency
rates have been reported with cuffed ePTFE than with
standard ePTFE grafts.17,18 Patients were randomized into
the two groups by an independent study coordinator. A
flow diagram representing the randomization and patients
excluded can be seen in Fig 1.
All patients signed written informed consent before
enrollment in this study. All patients underwent evaluation,
both preoperatively and postoperatively, and had their
grafts placed at the MGH. The objective of this study was
to understand differences in patency and frequency of
complications between the BCA and ePTFE grafts. Further
analysis was undertaken to determine if the location of graft
placement influenced the patency or complication rate.
Mean length of follow-up was up to 33 months. This study
was approved by the Institutional Review Board of the
MGH.
Hemodialysis access algorithm. We follow the
KDOQI guidelines for creation of native AVF or AV grafts.
AV grafts are used only in patients that are not suitable for
native AVFs. A minimum inflow arterial and outflow ve-
nous diameter of 3 mm is required for all patients under-
going placement of AVGs.
Graft placement. All forearm grafts were loop grafts
with the arterial anastomosis to the brachial artery and the
venous anastomosis to the cephalic or other suitably sized
antecubital vein. The upper arm grafts were placed in a
gentle C-shaped curve from the brachial artery, just above
the antecubital crease, to the axillary vein.When placing the
BCA grafts, the arterial anastomosis is created before the
venous anastomosis. This allows the graft to become en-
gorged with blood and decreases the potential for twists or
kinks to occur during the tunneling process.
Graft monitoring and utilization. Each patient was
Fig 1. Flow diagram representingevaluated at the conclusion of the operation and again in bable I. Baseline patient characteristics
haracteristic
BCA
(n  26)
ePTFE
(n  27) P value
gea 63  13 59  16 .325
enderb 1
Male 13 14
Female 13 13
aceb .163
White 21 14
African American 2 7
Hispanic 2 4
Asian 1 2
raft locationb .786
Upper arm 13 15
Forearm 13 12
nesthesiab .669
Monitored anesthesia care 24 23
General anesthesia 2 4
Lowest systolic BPa 121  20 143  30 .003
Lowest diastolic BPa 61  10 71  13 .002
omorbiditiesb
Diabetes 17 16 .779
Hypertension 14 22 .042
Coronary artery disease 14 8 .098
Congestive heart failure 4 1 .192
Obesity 1 2 1
Peripheral vascular disease 0 1 1
umber of previous AV graftsb .855
0 19 20
1 2 3
2 3 3
3 2 1
umber of previous AV fistulab .654
0 15 13
1 6 9
2 4 5
3 1 0
V, Arteriovenous; BCA, bovine carotid artery; BP, blood pressure; ePTFE,
xpanded polytetrafluoroethylene.
Plus-minus values are means  SD.
Numbers are counts of the number of patients in each category.
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June 20111642 Kennealey et althe recovery room by the operating surgeon for the pres-
ence of a thrill and audible bruit within the graft. When the
patient was awake and alert, sensation, capillary refill, and
strength of the ipsilateral hand were further assessed by the
recovery room nurse. All patients underwent physical ex-
amination by the operating surgeon 2 weeks postsurgery
and then at 4 to 6 weeks postsurgery. All grafts were
monitored according to the KDOQI guidelines,1 and the
protocol for monitoring was exactly the same in both
groups. In brief, all grafts were monitored for the presence
of a thrill and audible bruit by a trained dialysis nurse at the
time of hemodialysis. The absence of a thrill or bruit
resulted in immediate notification of the MGH Vascular
Access coordinator. Patients were then routed for either
surgical evaluation (grafts4 weeks from placement) or for
interventional radiology evaluation (grafts 4 weeks from
placement). If endovascular intervention was unsuccessful,
patients were referred for surgical evaluation. Furthermore,
if patients developed problems with the flow pattern or
increased bleeding at the end of a dialysis run, they were
referred expeditiously for radiographic evaluation. Surveil-
lance angiographic imaging was not performed in either the
BCA or ePTFE group.
Infection was defined by the presence of erythema at
the surgical incision and need for intravenous antibiotics or
surgical intervention. Steal syndrome was defined accord-
ing to the four stages of ischemia: stage I  pale/blue
Fig 2. Overall results. A, Primary patency rates. B, As
assisted primary patency rates were significantly higher (P
(BCA) group than expanded polytetrafluoroethylene (eP
patency between BCA and ePTFE.and/or cold hand without pain; stage II  pain during Bxercise and/or hemodialysis; stage III  rest pain; and
tage IV  ulcers/necrosis/gangrene.19 Surgical interven-
ion was undertaken for patients with stage III or IV steal.
BCA grafts are accessed in the same manner as a native
VF. Needles are inserted at a 25 to 30° angle. Typically,
he first access is done with a 17-gauge needle and over time
nlarged to a 15-gauge needle. With ePTFE grafts, a 15-
auge needle is used from the start.
Definition of graft patency. We used the Reporting
tandards: Recommended Standards for Reports Dealing
ith Arteriovenous Hemodialysis Access20 as our guide for
omenclature and complication descriptions. Primary pa-
ency is defined as the interval from graft implantation to
ny intervention for stenosis with or without complete
cclusion (thrombosis). Assisted primary patency is defined
s the interval from graft implantation to the first episode of
omplete occlusion. Secondary patency is defined as the
nterval from graft implantation to graft failure.
Statistical analysis. All data for this study were ob-
ained from the MGH Vascular Access database. Primary
nd secondary patency was calculated using Kaplan-Meier
urvival curve analysis utilizing Prism version 4 (GRAPH
ad Software, San Diego, Calif), which compares curves
sing the log-rank test. Baseline variables for which a mean
nd SD were reported were compared using the t test;
onfidence intervals for each of our primary comparisons at
2 and 24 months were calculated as Confidence Interval 
primary patency. C, Secondary patency. Primary and
062 and .012, respectively) in the bovine carotid artery
) group. There is no statistical difference in the secondsisted
 .0
TFECA Survival (%) -PTFE Survival (%)  1.96  BCA
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Volume 53, Number 6 Kennealey et al 1643(SE)  2 -PTFE (SE)  2.21,22 For comparisons of cate-
gorical baseline variables we used the Fisher exact test, and
for comparisons of ordinal baseline variables we used the
Wilcoxon-Mann-Whitney test. Poisson regression was used
to evaluate and compare procedures per patient year
(PROC GENMOD in SAS, version 9.2). Poisson regres-
sion was performed on the log scale and the delta-method
was applied to transform the SEs in these tables. Although
multiple comparisons were performed, the significance of
each intervention was tested individually. Due to the small
sample sizes, only upper arm and forearm grafts were
considered when graft location was included in the analy-
ses. A P value .05 was considered significant.
RESULTS
Demographics. After randomization, there were 26
patients in the BCA group and 27 patients in the ePTFE
group.Within the BCA group, there were 13 forearm grafts
and 13 upper arm C-shaped curved grafts. In the ePTFE
group, there were 12 forearm grafts, 15 upper arm grafts,
and 1 upper arm loop graft. All grafts placed as part of this
study were successfully used for hemodialysis. Patient de-
mographic data are presented in Table I. With the excep-
Table II. A, Overall results
Graft/months 0 4 8 12
Primary patency
BCA
N 26 18 15 14
Mean (%) 100 69 64.8 60.5
SE 0 9.1 9.4 9.7
ePTFE
N 27 13 7 5
Mean (%) 100 44.1 20.2 10.1
SE 0 9.6 8.5 6.6
Confidence interval 38.7
(Lower and upper) 61.3
Primary assisted patency
BCA
N 26 19 16 15
Mean (%) 100 72 64.8 60.5
SE 0 8.7 9.4 9.7
ePTFE
N 27 13 7 5
Mean (%) 100 44.4 31.2 20.8
SE 0 9.5 9.4 8.7
Confidence interval 27.7
(Lower and upper) 51.6
Secondary patency
BCA
N 26 24 20 18
Mean (%) 100 92.1 64.7 60.1
SE 0 5.3 9.5 9.9
ePTFE
N 27 23 19 15
Mean (%) 100 88.6 88.6 73.2
SE 0 6.2 6.2 9.6
Confidence interval 5.6
(Lower and upper) 17.9
BCA, Bovine carotid artery; ePTFE, expanded polytetrafluoroethylene.tion of hypertension and intraoperative blood pressure, Phere were no significant differences in patient demograph-
cs when comparing the BCA and the ePTFE groups.
Patency. In the BCA group, four patients underwent
even interventions before the first episode of thrombosis,
hich was not significantly different from the ePTFE group
five patients underwent six interventions). The overall
rimary patency of the BCA grafts was 60.5% compared to
0.1% in the ePTFE group at 1 year, P  .0062 (Fig 2, A;
able II, A). Graft assisted primary patency for the BCA
nd ePTFE groups is represented in Fig 2, B and Table II,
. Assisted primary patency rates were also significantly
igher in the BCA grafts (60.5% at 1 year, 40.5% at 2 years)
ompared to the ePTFE grafts (20.8% at 1 year and 13.8%
t 2 years) P  .012. However, there was no significant
ifference in the secondary patency between BCA and
PTFE grafts (64.1% vs 59.2% at 2 years, respectively; Fig 2,
; Table II, A). Further analysis of these two groups
emonstrated a profound graft survival advantage in pa-
ients that received the BCA in the upper arm. As seen in
ig 3 and Table II, B, the primary and assisted primary
atency rates of the upper arm graft were significantly
igher in the BCA (84.6% and 84.6% at 1 year, respectively)
han in the ePTFE (11.1% and 11.1% at 1 year, respectively;
16 20 24 28 32 36 40
9 5 1 1 1 1 1
4.1 38.5 19.3 19.3 19.3 19.3 19.3
0.7 10.7 14.6 14.6 14.6 14.6 14.6
2 2 2 1 1 1 1
0.1 10.1 10.1 10.1 10.1 10.1 10.1
6.6 6.6 6.6 6.6 6.6 6.6 6.6
3.6
22
0 6 2 2 2 1 1
0.5 40.5 40.5 40.5 40.5 40.5 40.5
0.4 10.4 10.4 10.4 10.4 10.4 10.4
2 2 2 1 1 1 1
3.8 13.8 13.8 13.8 13.8 13.8 13.8
8.1 8.1 8.1 8.1 8.1 8.1 8.1
14.8
38.7
6 10 6 4 4 2 1
3.2 73.2 64.1 64.1 64.1 64.1 64.1
9.6 9.6 12 12 12 12 12
0 8 4 2 2 2 2
9.2 59.2 59.2 59.2 59.2 59.2 59.2
1.8 11.8 11.8 11.8 11.8 11.8 11.8
8.6
18.54
1
1
1
4
1
1
1
7
1
5
1 .0001 and .0005, respectively). However, again, there
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June 20111644 Kennealey et alwas no statistical difference in the secondary patency in the
upper arm grafts (Fig 3, C and Table II, B). The secondary
patency was slightly better in the ePTFE forearm grafts
compared with the BCA forearm grafts (Fig 4,C and Table
II, C), although this did not reach statistical significance.
In this study population, the total number of interven-
tions per patient year needed to prolong patency was
1.45 0.19 in the BCAgroup and 1.99 0.25 in the ePTFE
group, P  .09. The most common intervention used to
achieve this secondary patency was percutaneous angio-
plasty performed by the interventional radiologists. There
were 1.19  0.18 angioplasties per patient year compared
to 1.86  0.24, P  .02, in the BCA and ePTFE groups,
respectively. The complete list of interventions and the
frequency with which they were used is listed in Table III.
When evaluating the frequency of interventions by
graft location, percutaneous angioplasty was necessary 2.49
0.43 times per patient year in upper arm ePTFE grafts
compared to 1.30  0.27 times per patient year in upper
arm BCA grafts, P  .014. There was no difference in
frequency of percutaneous angioplasty in the forearm
ePTFE or BCA grafts, Table IV.
Complications. The list of complications and their
Table II. B, Results of upper arm graft
Graft/months 0 4 8
Primary patency
BCA
N 13 11 10
Mean (%) 100 84.6 84.6
SE 0 10 10
ePTFE
N 15 6 2
Mean (%) 100 33.3 11.1
SE 0 12.2 9.9
Confidence interval
(Lower and upper)
Primary assisted patency
BCA
N 13 11 10
Mean (%) 100 84.6 84.6
SE 0 10 10
ePTFE
N 15 7 3
Mean (%) 100 33.3 11.1
SE 0 12.2 9.9
Confidence interval
(Lower and upper)
Secondary patency
BCA
N 13 12 11
Mean (%) 100 92.3 92.3
SE 0 7.4 7.4
ePTFE
N 15 12 9
Mean (%) 100 78.9 78.9
SE 0 10.8 10.8
Confidence interval
(Lower and upper)
BCA, Bovine carotid artery; ePTFE, expanded polytetrafluoroethylene.frequency are presented in Table V. The clinically signifi- gant graft-related complications encountered during this
tudy were thrombosis, infection, pseudoaneurysm, and
teal. The most common complication was graft thrombo-
is which occurred 0.77 0.16 times per patient year in the
PTFE group compared to 0.34  0.09 times per patient
ear in the BCA group, P  .01.
As seen in Table VI, patients receiving forearm grafts
eveloped clinically relevant infection more commonly if
hey had BCA grafts (P .039), whereas if they had upper
rm grafts, infection was more common in the ePTFE
rafts (P  .008). There was no statistically significant
ifference in the rate of thrombosis, pseudoaneurysm for-
ation, or arterial steal syndrome between the BCA and
PTFE groups within either graft location subset.
ISCUSSION
The primary purpose of this randomized study was to
ompare patency and complication rates among patients
eceiving BCA grafts to those receiving the established
tandard ePTFE grafts. Our results demonstrate the as-
isted primary patency of BCA grafts to be superior to
PTFE conduits, whereas no statistical difference is appre-
iable in the secondary patency rates. Furthermore, BCA
2 16 20 24 28 32
6 3 2 1 1
.6 60.4 48.4 24.2 24.2 24.2
16.1 16.8 19.1 19.1 19.1
0 0 0 0 0
.1 0 0 0 0 0
.9 0 0 0 0 0
.8 12
.4 36.3
6 3 3 2 2
.6 60.4 60.4 60.4 60.4 60.4
16.1 16.1 16.1 16.1 16.1
0 0 0 0 0
.1 0 0 0 0 0
.9 0 0 0 0 0
.1 49.3
.9 71.5
9 5 5 3 2
.3 92.3 79.1 79.1 79.1 79.1
.4 7.4 13.8 13.8 13.8 13.8
5 4 2 1 1
.3 59.3 47.4 47.4 47.4 47.4
.6 14.6 15.7 15.7 15.7 15.7
.8 9.4
.5 39.71
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overall complication rate.
Primary patency is defined as the interval from graft
implantation to any intervention for stenosis with or with-
out complete occlusion (thrombosis).20 It is important to
point out that this is somewhat of a subjective end point as
it relies on the dialysis technician or nurse to recognize and
appropriately refer patients with high venous pressure dur-
Table II. C, Results of forearm graft
Graft/months 0 4 8
Primary patency
BCA
N 13 8 6
Mean (%) 100 53.8 46.1
SE 0 13.8 13.8
ePTFE
N 12 7 4
Mean (%) 100 50 30
SE 0 14.4 13.9
Confidence interval
(Lower and upper)
Primary assisted patency
BCA
N 13 9 7
Mean (%) 100 61.5 53.9
SE 0 13.5 13.9
ePTFE
N 12 7 5
Mean (%) 100 58.3 40
SE 0 14.4 14.6
Confidence interval
(Lower and upper)
Secondary patency
BCA
N 13 13 10
Mean (%) 100 92.3 83.9
SE 0 7.4 10.4
ePTFE
N 12 12 11
Mean (%) 100 100 100
SE 0 0 0
Confidence interval
(Lower and upper)
BCA, Bovine carotid artery; ePTFE, expanded polytetrafluoroethylene.
Table III. Number of procedures per patient year
Procedure
BCA
(n 26)
ePTFE
(n 27) P value
Total interventions 1.45 0.19 1.99 0.25 .08
Endovascular thrombectomy 0.70 0.13 0.77 0.16 .72
Endovascular angioplasty 1.26 0.18 1.89 0.25 .04
Venous 1.11 0.17 1.86 0.24 .01
Arterial 0.03 0.03 0— .28
Central 0— 0.03 0.03 .2
Intragraft 0.13 0.06 0— .02
Endovascular stent 0.05 0.04 0.03 0.03 .69
Surgical revision 0.10 0.05 0.06 0.05 .57
Surgical thrombectomy 0.13 0.06 0.10 0.06 .69
BCA, Bovine carotid artery; ePTFE, expanded polytetrafluoroethylene.ing dialysis or excessive bleeding after a dialysis treatment. latients with these symptoms of venous stenosis do typi-
ally require endovascular intervention to prolong patency.
s a result of this limitation in our study, we feel that the
ssisted primary patency and secondary patency results are
ore useful data points to evaluate.
Upon interpreting our results, we were concerned by
he low assisted primary patency rate of the ePTFE cohort
20.8% at 1 year). However, numerous prospective studies
valuating the standard ePTFE grafts report primary or
ssisted primary patency rates that range from 10% to as
igh as 43%.18,23-26 Two recent prospective studies of
uffed ePTFE grafts also reported widely discrepant re-
ults.18,27 The first study from the Mayo Clinic demon-
trated a 1-year primary patency rate for cuffed ePTFE (n
4) and standard ePTFE (n 24) grafts of 35% and10%,
espectively. The second study from Taiwan reported a
-year primary patency rate for cuffed (n  47) and stan-
ard ePTFE (n  42) as 63% vs 50%, respectively. In our
wn retrospective study comparing cuffed vs standard
PTFE grafts, the assisted primary patency rates were 37.7%
s 25.7%, respectively.17 In light of those studies, the
ssisted primary patency in cuffed ePTFE grafts in the
urrent study was obviously lower and was almost equiva-
2 16 20 24 28 32
4 3 1 1 1
.9 27.7 27.7 27.7 27.7 27.7
.8 13.1 13.1 13.1 13.1 13.1
2 2 2 2 1
20 20 20 20 20
.4 12.4 12.4 12.4 12.4 12.4
.7 6.2
.1 21.7
5 4 1 1 1
.8 35.9 35.9 35.9 35.9 35.9
.1 13.9 13.9 13.9 13.9 13.9
2 2 2 2 1
30 30 30 30 30
.6 13.9 13.9 13.9 13.9 13.9
.7 8.7
.5 20.5
8 6 2 2 2
.6 74.6 74.6 55.9 55.9 55.9
.8 12.8 12.8 18.8 18.8 18.8
6 5 4 3 2
.9 88.9 71.1 71.1 71.1 71.1
.5 10.5 17.9 17.9 17.9 17.9
31
.9 1.61
5
36
13
3
20
12
2
31
6
44
14
4
40
14
8
20
8
74
12
9
88
10
27
0ent to the results of the standard ePTFE grafts of our own
difference in the second patency between BCA and ePTFE.
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June 20111646 Kennealey et alFig 4. Results of forearm graft. A, Primary patency rates. B, Assisted primary patency. C, Secondary patency. There
is no statistical difference observed in primary, assisted primary, and secondary patency rates in forearm arteriovenousFig 3. Results of upper arm graft. A, Primary patency rates. B, Assisted primary patency. C, Secondary patency.
Primary and assisted primary patency rates were significantly higher (P  .0001 and P  .0005, respectively) in the
bovine carotid artery (BCA) group than in the expanded polytetrafluoroethylene (ePTFE) group. There is no statisticalgraft (AVG). BCA, Bovine carotid artery; ePTFE, expanded polytetrafluoroethylene.
t
c
e
c
a
t
g
n
u
l
B
t
o
l
o
F
A
C
A
D
W
C
F
S
O
O
JOURNAL OF VASCULAR SURGERY
Volume 53, Number 6 Kennealey et al 1647retrospective study. It is difficult to reconcile the differences
in these patency rates especially given the differences found
at our own center in the hands of the same surgeons. This
difference may be attributable to the relatively small num-
ber of participants and is certainly a limitation of this
current study. Nevertheless, the assisted patency rate of
60.5% at 1 year in BCA grafts is clearly higher than those
observed in most previous prospective studies on ePTFE
grafts.
Our initial experience with the BCA graft began in
2004 and our early impression of this conduit was that it
resulted in less inflammatory response at the site of implan-
tation and less infectious complications while also allowing
for easier surgical handling. On the other hand, our major
concern was the long-term durability of the graft. In this
study, with a mean follow-up of 33 months, we demon-
strate a significantly lower incidence of thrombosis in the
BCA cohort.
A common cause of AV graft thrombosis is due to
neointimal hyperplasia that develops at the site of the
vascular anastomosis.28,29 The cause of neointimal hyper-
plasia is multifactorial but mechanical stress that results
from luminal hypertension and compliance mismatch be-
Table IV. Number of interventions per patient year
Procedure
Forearm
BCA (n  13) ePTFE (n 
Total interventions 1.32  0.28 1.62  0.
Endovascular angioplasty 0.96  0.24 1.45  0.
Endovascular stent 0 — 0 —
Surgical revision 0.12  0.08 0.06  0.
Surgical thrombectomy 0.18  0.10 0.12  0.
Endovascular thrombectomy 0.42  0.16 0.75  0.
BCA, Bovine carotid artery; ePTFE, expanded polytetrafluoroethylene.
Table V. Number of complications per patient year
Type
BCA
(n  26)
ePTFE
(n  27) P value
Thrombosis 0.34  0.09 0.77  0.16 .01
Infection 0.10  0.05 0.13  0.06 .76
Pseudoaneurysm 0 — 0.06  0.05 .07
Steal 0.03  0.03 0.03  0.03 .88
BCA, Bovine carotid artery; ePTFE, expanded polytetrafluoroethylene.
Table VI. Number of complications per patient year
Procedure
Forearm
BCA (n  13) ePTFE (n  12)
Thrombosis 0.420  0.159 0.812  0.217
Infection 0.180  0.104 0 —
Pseudoaneurysm 0 — 0 —
Steal 0 — 0 —BCA, Bovine carotid artery; ePTFE, expanded polytetrafluoroethylene.ween the vessel wall and graft is thought to be a major
ontributing factor.29 Elasticity mismatch between the stiff
PTFE graft and elastic native tissue at the anastomosis site
auses wall stress, leading to cell proliferation.30,31 One
pproach to solve the problem of compliance mismatch is
o use more elastic material such as decellularized xeno-
rafts, as AV grafts29 elastic mismatch problem is to use
atural, instead of synthetic material. Although only spec-
lative, the lower rate of graft thrombosis may be due to
ess or slower developing neointimal hyperplasia in the
CA group. Further study is certainly required to validate
his hypothesis.
In summary, BCA conduits are an excellent alternative
ption for hemodialysis AV grafts. Additional studies with
arger numbers and longer follow-up are needed to validate
ur results.
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Upper arm
P value BCA (n  13) ePTFE (n  15) P value
.47 1.34  0.27 2.57  0.44 .01
.19 1.39  0.27 2.57  0.44 .02
0.11  0.08 0.08  0.08 .77
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